ArticleBMC cardiovascular disorders2025
Contribution of albumin-corrected anion gap and associated biomarkers to the mortality of patients with congestive heart failure: a retrospective cohort study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAlbumin-corrected anion gap (ACAG) is a prognostic biomarker for various diseases. As a derived metric, the relationship between ACAG and potential related biomarkers, along with their combined effect on death, has yet to be fully elucidated. This study aims to investigate the association between ACAG and mortality of congestive heart failure (CHF), and to identify the specific biomarkers related to increased ACAG and the risk of mortality in CHF.
methodsThis study selected patients with CHF in intensive care units (ICU) from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Patients were stratified based on their ACAG levels into four groups. The outcomes were 28-day and 1-year mortality of CHF. Cox proportional hazard analysis and subgroup analysis were performed to explore the predictive value of ACAG. The mediation analysis and Pearson correlation analysis were used to explore potential associated biomarkers.
resultsA total of 2,689 patients with CHF were included in this study. Of these, 697 and 1,207 patients died within 28 days and 1 year, respectively. Cox proportional hazard analysis showed that increased ACAG level was significantly associated with both 28-day and 1-year mortality (hazard ratio [HR]: 2.18, 95%CI: [1.67, 2.84] and HR: 1.44, 95%CI: [1.18, 1.74], respectively) after adjusting for confounding factors. The subgroup analysis demonstrated that ACAG exhibited a pronounced predictive value among patients admitted to the coronary care unit (CCU), or with myocardial infarction in both 28-day and 1-year mortality. The mediating effect of ACAG was found to be significant between lactate, phosphate and blood urea nitrogen (BUN) concerning 28-day mortality (mediated proportion: 44.0%, 37.4% and 16.5%, respectively), but not 1-year mortality. All three biomarkers showed significant correlations with ACAG.
conclusionsElevated ACAG was a significant risk factor for 28-day and 1-year mortality in critically ill patients with CHF. ACAG plays an important role in mediating the association between lactate, phosphate and BUN and 28-day death in CHF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.